Smoking Cessation Aids Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Smoking Cessation Aids Market is segmented by Products (Nicotine Replacement Therapy, Drugs, Electronic Cigarettes and Others), End-user and Geography

Market Snapshot

smoking cessation and nicotine de addiction products market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 12.5 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Smoking Cessation Aids Market is expected to witness a CAGR of 12.5% during the forecast period. Smoking is one of the major causes of lung cancer and other respiratory and cardiac diseases. Awareness about these health hazards has influenced the individuals to adopt smoking cessation therapy. The awareness among the individuals is through digital media, print media and other sources of information has proved to be effective in curbing nicotine addiction crisis to some extent.

Cigarette smoking remains the leading cause of preventable disease, disability, and death. According to Centers for Disease Control and Prevention (CDC), In 2019, nearly 14 of every 100 U.S. adults aged 18 years or older (14.0%) smoked cigarettes. This hints at a high usage of de-addiction products. Also, this depicts the growing awareness of the people and their readiness to quit smoking. There are also non-government and government establishments working to educate and help people quit smoking that is engaged dedicatedly, to bring the number of smokers down. For instance, in 2017, the US Food and Drug Administration launched an adult smoking cessation education campaign aimed at encouraging cigarette smokers to quit smoking.

Other factors that will help the market growth during the forecast period, include the introduction of new products and reimbursement for smoking cessation therapy.

Scope of the Report

As per the scope of the report, tobacco use can lead to tobacco/nicotine dependence and serious health problems. Quitting smoking greatly reduces the risk of developing smoking-related diseases. Tobacco/nicotine dependence is a condition that often requires repeated treatments, but there are helpful treatments and resources for quitting. Tobacco smoke contains a deadly mix of more than 7,000 chemicals, of which hundreds, are harmful, and about 70 can cause cancer. Smoking increases therefore increases the risk of serious health problems, many diseases, and death. People who stop smoking greatly reduce their risk of disease and early death.

Product
Nicotine Replacement Therapy
NRT Gum
NRT lozenges
NRT Inhalers
NRT Patches
Sprays
Drugs
Electronic Cigarettes
Others
End-user
Hospital Pharmacies
Online Channel
Retail Pharmacies
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

E-cigarettes Technology is Expected to Show Steady Growth Over the Forecast Period

E-cigarettes are considered as a healthy alternative to tobacco cigarettes and is estimated to be the fastest growing segment over the forecast period. E-cigarettes are an effective alternative for reducing health conditions associated with tobacco, while nicotine replacement therapies work best for smoking cessation. E-cigarettes are a potential threat to tobacco-based cigarettes.

At the same time, an opportunity for tobacco manufacturers to enter the new emerging segment catering to the smoking population. Consumption of e-cigarettes are less harmful compared to the regular cigarettes, no smoke and no risk of passive smoking, allowed to use even in no-smoking places, varying nicotine levels, and availability in various flavors are some of the major driving factors for the e-cigarettes market. in addition, the increasing popularity of e-cigarettes backed by its electronic feature is considered to be the major factor contributing towards its increasing demand.

Percentage of Adults Smoking, By Age Group (yrs.), United States, 2019

Asia-Pacific Expected to Expected to Show Fastest Growth over the Forecast Period

Asia-Pacific is expected to be the fastest growing region for the market, due to increasing awareness about the smoking cessation and nicotine de-addiction products, and a huge population base in the area. In a study called Tobacco Smoking and Mortality in Asia published by JAMA Network March 2019, a pooled meta-analysis, an international collaboration of researchers, led by those from Vanderbilt University, United States, has studied the trends in tobacco use in China, Japan, South Korea, Singapore, Taiwan, and India. It was estimated that 8.3 million deaths will be attributed to smoking by 2030, half of the world's male smokers live in China, India, and Indonesia and Asia is the world's largest tobacco consumer and producer.

North America is also found dominating the smoking cessation market due to the established healthcare infrastructure and the rising disposable income.

Smoking Cessation Aids Market 2

Competitive Landscape

The market players in the smoking cessation aids market involve various growth strategies, such as collaborations, partnerships, agreements, mergers and acquisitions in order to enhance the market presence. Furthermore, the introduction of new products, collaborations with government and NGO's to create awareness of smoking cessation also boosts the market growth. 

Recent Developments

In July 2020, Dr. Reddy's Laboratories launched OTC Nicotine Polacrilex Lozenges in the United States. The Nicotine lozenges brands and store brand markets witnessed United States retail sales of about USD 200 million in 2020. The product is a significant addition to the company’s offering of Nicotine Replacement Therapy.

In April 2020, Philip Morris Products S.A.’s product IQOS Tobacco Heating System was authorized by the United States Food and Drug Administration (USFDA) for marketing and distribution.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Large Population Addicted to Smoking

      2. 4.2.2 Awareness on Hazards of Smoking

      3. 4.2.3 Banning Advertisements of Tobacco Products

    3. 4.3 Market Restraints

      1. 4.3.1 Adverse effects of Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Product

      1. 5.1.1 Nicotine Replacement Therapy

        1. 5.1.1.1 NRT Gum

        2. 5.1.1.2 NRT lozenges

        3. 5.1.1.3 NRT Inhalers

        4. 5.1.1.4 NRT Patches

        5. 5.1.1.5 Sprays

      2. 5.1.2 Drugs

      3. 5.1.3 Electronic Cigarettes

      4. 5.1.4 Others

    2. 5.2 End-user

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Online Channel

      3. 5.2.3 Retail Pharmacies

      4. 5.2.4 Other End Users

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 NJOY

      2. 6.1.2 Pfizer Inc.

      3. 6.1.3 GlaxoSmithKline Plc

      4. 6.1.4 F. Hoffmann-La Roche AG

      5. 6.1.5 Novartis AG

      6. 6.1.6 Johnson and Johnson

      7. 6.1.7 Bayer AG

      8. 6.1.8 Cipla Ltd

      9. 6.1.9 Takeda Pharmaceuticals Co. Ltd.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Smoking Cessation Aids Market market is studied from 2018 - 2026.

The Smoking Cessation Aids Market is growing at a CAGR of 12.5% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Johnson and Johnson, Takeda Pharmaceuticals Co. Ltd., NJOY, Pfizer Inc., Cipla Ltd. are the major companies operating in Smoking Cessation Aids Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!